Ozra Akha

Ozra Akha

Auto-generated profile, based on publicly available information

Ozra Akha

Department of Internal Medicine, Diabetes Research Center, Faculty of Medicine Mazandaran University of Medical Sciences Sari Iran

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in Medicine
Verified
Journal Article
Open access
ABAdeleh Bahar
Adeleh Bahar
ZKZahra Kashi
Zahra Kashi
EDEzzatossadat Daneshpour
Ezzatossadat Daneshpour
OAOzra Akha
Ozra Akha
SAShahram Ala
Shahram Ala
Cabergoline is a long-acting agonist of dopamine, which has a high affinity to dopamine receptors (type 2). Treatment using a dopaminergic agonist reduces hypothalamic stimulation that increases during liver gluconeogenesis, lipids synthesis, and insulin resistance. Our aim was to evaluate the effects of cabergoline on blood glucose levels in patients with type 2 diabetes mellitus (DM). This study was a double-blind, controlled clinical trial in patients with type 2 DM. The patients received treatments of a placebo (control group; n = 20) or cabergoline 0.5 mg (cabergoline group; n = 20) using the sequential method, once per week for 3 months, while using previously prescribed glucose-lowering drugs. All tests, such as levels of fasting blood glucose, 2-hour post-prandial glucose, complete lipid profile, prolactin, alanine amino transferase, aspartate amino transferase, creatinine, blood urea nitrogen, and serum insulin, and homeostasis model assessment insulin resistance were measured at baseline and at 3-month follow-up. The fasting blood sugar levels were significantly different between placebo and cabergoline groups after 3 months of treatment (P = 0.004). The prolactin levels were significantly different from beginning of the treatment to 6 months later (P = 0.001). In the cabergoline group, there was a significant decrease in glycosylated hemoglobin (HbA1C) levels after 3 months (P = 0.003). Overall, 65%and 45% patients in the cabergoline and control groups, respectively, responded to treatment (HbA1C<7%). Cabergoline may be useful as a long-acting antidiabetic agent in patients with type 2 diabetes mellitus.

1 October 2011
Verified
Journal Article
Closed access
ZHZ. Hajheydari
Z. Hajheydari
ZKZ. Kashi
Z. Kashi
OAO. Akha
O. Akha
SAS. Akbarzadeh
S. Akbarzadeh

31 July 2015 in Global Journal of Health Science
Verified
Journal Article
Open access
PDF file
ZKZahra Kashi
Zahra Kashi
ABAdeleh Bahar
Adeleh Bahar
OAOzra Akha
Ozra Akha
SHSamane Hassanzade
Samane Hassanzade
LELeila Esmaeilisaraji
Leila Esmaeilisaraji
ZHZeinab Hamzehgardeshi
Zeinab Hamzehgardeshi
BACKGROUND: Untreated maternal hypothyroidism can have adverse effects on both the mother and fetus, but it can potentially be prevented by adequate levothyroxine replacement. This study was conducted to determine what percentage of hypothyroid pregnant women who were taking levothyroxine needed to adjust their medication dosage, and when and how much it should be increased.METHODS: In this longitudinal study, 81 well-controlled hypothyroid women (TSH≤ 2.5 mIU/L) were monitored throughout pregnancy. Thyroid function tests were performed before conception, after the first missed menstrual period, in the second and third trimesters of pregnancy and one month after delivery. Levothyroxine dosage was adjusted according to TSH levels measured. RESULTS: Of the 81 pregnancies studied, the pregnancy outcomes were 74 full-term births, six abortions and one pre-term birth. The levothyroxine dosage needed to be increased in 84% (CI95%= 74-90) of the pregnancies (OR=5.2, CI95%= 2.9-9.4). Most levothyroxine dose adjustments were made in the first trimester of gestation. The levothyroxine requirement increased 50% (CI95%= 41-59) in the first trimester, 55% (CI95%= 45-64) in the second trimester and 62% (CI95%= 52-72) in the third trimester. Levothyroxine dosage was decreased for 6 cases (7.4%), and no adjustment was made for 7 women (8.6%).CONCLUSIONS: Increases in levothyroxine dosage administered in pregnancy appear to be indispensible in the majority of patients with well-controlled hypothyroidism, especially in the first trimester. However, this change was not universal and levothyroxine dosage decreased in a few cases and remained unchanged in others.

14 January 2014 in Nephro-Urology Monthly
Verified
Journal Article
Open access
PDF file
AMAtieh Makhlough
Atieh Makhlough
ZKZahra Kashi
Zahra Kashi
OAOzra Akha
Ozra Akha
EZEhsan Zaboli
Ehsan Zaboli
JCJamshid Yazdani- Charati
Jamshid Yazdani- Charati
Background: Diabetic nephropathy is the most important cause of end stage renal disease (ESRD). Aldosterone is involved in renal damage through induction of fibrosis, inflammation and necrosis in the kidney tissue. Previous studies have demonstrated that the combination of angiotensin receptor blocker (ARB) and spironolactone (an anti-aldosterone drug) are efficient for albuminuria reduction. Objectives: This study was designed to evaluate the effect of spironolactone alone on diabetic nephropathy. Patients and Methods: In this double blind randomized clinical trial, 60 type II diabetic patients with microalbuminuria were enrolled. They were divided into two groups: case group (spironolactone 25 mg and placebo, 30 cases) and control (spironolactone 25 mg plus losartan 25 mg, 30 cases). The treatment success rate (more than 50% reduction in microalbuminuria) was compared between the two groups. Results: After three months, successful treatment was seen in 70% (95% CI: 52 - 83) and 83.3% (CI 95%: 66 - 93) of case and control groups, respectively (P = 0.4). Mean ± SD of serum potassium levels after three months in case and control groups were 4.56 ± 0.38 and 4.39 ± 0.34 mEq/L, respectively (P = 0.08). Mean ± SD of systolic blood pressures in case and control groups were 129.67 ± 9.4 and 130.97 ± 9.4 mmHg, respectively (P = 0.6). Mean ± SD of serum creatinine levels at the end of the study were 0.95 ± 0.15 in case and 0.90 ± 0.22 mg/dL in control group (P = 0.4). Conclusions: Spironolactone alone is as effective as the combination of spironolactone and losartan on albuminuria reduction in type 2 diabetic patients and can be used alone as an effective drug for diabetic nephropathy. Keywords: Diabetic Nephropathy; Diabetes Mellitus, Type 2; Albuminuria; Spironolactone

1 March 2016
Verified
Journal Article
Closed access
MZMarsa Zaroudi
Marsa Zaroudi
JCJamshid Yazdani- Charati
Jamshid Yazdani- Charati
SMSharmin Mehrabi
Sharmin Mehrabi
EGElham Ghorbani
Elham Ghorbani
JNJalal Norouzkhani
Jalal Norouzkhani
AMAkbar Fazel-tabar Malekshah
Akbar Fazel-tabar Malekshah

7 June 2015 in International Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
SAS. Ala
S. Ala
OAO. Akha
O. Akha
ZKZ. Kashi
Z. Kashi
ABAdeleh Bahar
Adeleh Bahar
HRH. Askari Rad
H. Askari Rad
ASA. Shiva
A. Shiva
Background. Levothyroxine is commonly used in the treatment of patients with hypothyroidism. Levothyroxine is most often administered in the morning, on an empty stomach, in order to increase its oral absorption. However, many patients have difficulties taking levothyroxine in the morning. Aim. The aim of this study was evaluating the effect of changing levothyroxine administration time from before breakfast to before dinner on the serum levels of TSH and T4. Subjects and Methods. Fifty patients between 18 and 75 years old with hypothyroidism were included in the study and were randomly divided into two groups. Each group received two tablets per day (one levothyroxine tablet and one placebo tablet) 30 minutes before breakfast and 1 hour before dinner. After two months, the administration time for the tablets was changed for each group, and the new schedule was continued for a further two-month period. The serum TSH and T4 levels were measured before and after treatment in each group. Results. Changing the levothyroxine administration time resulted in 1.47 ± 0.51µIU/mL increase in TSH level () and 0.35 ± 1.05µg/dL decrease in T4 level (). Conclusions. Changing the levothyroxine administration time from before breakfast to before dinner reduced the therapeutic efficacy of levothyroxine.